Hr mds


In MDS, is higher risk higher reward?

1. Greenberg P, Cox C, LeBeau MM, et al. . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. [PubMed] [Google Scholar]

2. Greenberg PL, Tuechler H, Schanz J, et al. . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465. [PMC free article] [PubMed] [Google Scholar]

3. Pfeilstöcker M, Tuechler H, Sanz G, et al. . Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128(7):902-910. [PMC free article] [PubMed] [Google Scholar]

4. Guralnik JM, Simonsick EM, Ferrucci L, et al. . A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85-M94. [PubMed] [Google Scholar]

5. Neo J, Fettes L, Gao W, Higginson IJ, Maddocks M. Disability in activities of daily living among adults with cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2017;61:94-106. [PubMed] [Google Scholar]

6. Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. . Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166-2172. [PubMed] [Google Scholar]

7. Palumbo A, Bringhen S, Mateos M-V, et al. . Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074. [PMC free article] [PubMed] [Google Scholar]

8. Bonanad S, De la Rubia J, Gironella M, et al. ; GAH Group. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. J Geriatr Oncol. 2015;6(5):353-361. [PubMed] [Google Scholar]

9. Deschler B, Ihorst G, Platzbecker U, et al. . Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98(2):208-216. [PMC free article] [PubMed] [Google Scholar]

10. Della Porta MG, Malcovati L, Strupp C, et al. . Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96(3):441-449. [PMC free article] [PubMed] [Google Scholar]

11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. [PubMed] [Google Scholar]

12. Sorror ML, Sandmaier BM, Storer BE, et al. . Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25(27):4246-4254. [PubMed] [Google Scholar]

13. Cutler CS, Lee SJ, Greenberg P, et al. . A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579-585. [PubMed] [Google Scholar]

14. Koreth J, Pidala J, Pérez WS, et al. . Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31(21):2662-2670. [PMC free article] [PubMed] [Google Scholar]

15. Platzbecker U, Schetelig J, Finke J, et al. ; Groupe Francophone des Myelodysplasies. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant. 2012;18(9):1415-1421. [PMC free article] [PubMed] [Google Scholar]

16. Kroeger N, Sockel K, Wolschke C, et al. . Prospective multicenter phase 3 study comparing 5-azacytidine (5-aza) induction followed by allogeneic stem cell transplantation versus continuous 5-aza according to donor availability in elderly MDS patients (55-70 years) (VidazaAllo study). Blood. 2018;132(suppl 1):208. [Google Scholar]

17. Shaffer BC, Ahn KW, Hu Z-H, et al. . Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. J Clin Oncol. 2016;34(16):1864-1871. [PMC free article] [PubMed] [Google Scholar]

18. de Witte T, Bowen D, Robin M, et al. . Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129(13):1753-1762. [PMC free article] [PubMed] [Google Scholar]

19. Della Porta MG, Gallì A, Bacigalupo A, et al. . Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2016;34(30):3627-3637. [PMC free article] [PubMed] [Google Scholar]

20. Yoshizato T, Nannya Y, Atsuta Y, et al. . Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129(17):2347-2358. [PMC free article] [PubMed] [Google Scholar]

21. Lindsley RC, Saber W, Mar BG, et al. . Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536-547. [PMC free article] [PubMed] [Google Scholar]

22. Alessandrino EP, Della Porta MG, Pascutto C, Bacigalupo A, Rambaldi A. Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?J Clin Oncol. 2013;31(21):2761-2762. [PubMed] [Google Scholar]

23. Scott BL, Storer B, Loken MR, Storb R, Appelbaum FR, Deeg HJ. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 2005;11(1):65-73. [PubMed] [Google Scholar]

24. Damaj G, Mohty M, Robin M, et al. . Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant. 2014;20(9):1349-1355. [PubMed] [Google Scholar]

25. Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;18(8):1211-1218. [PMC free article] [PubMed] [Google Scholar]

26. Damaj G, Duhamel A, Robin M, et al. . Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. J Clin Oncol. 2012;30(36):4533-4540. [PubMed] [Google Scholar]

27. Welch JS, Petti AA, Miller CA, et al. . TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375(21):2023-2036. [PMC free article] [PubMed] [Google Scholar]

28. Scott BL, Pasquini MC, Logan BR, et al. . Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35(11):1154-1161. [PMC free article] [PubMed] [Google Scholar]

29. Kröger N, Iacobelli S, Franke G-N, et al. . Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase III study of the EBMT (RICMAC Trial). J Clin Oncol. 2017;35(19):2157-2164. [PubMed] [Google Scholar]

30. Adhikari J, Sharma P, Bhatt VR. Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies. Future Oncol. 2015;11(23):3175-3185. [PubMed] [Google Scholar]

31. Rambaldi A, Grassi A, Masciulli A, et al. . Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16(15):1525-1536. [PubMed] [Google Scholar]

32. Beelen D, Markiewicz M, Stelljes M, et al. . Final evaluation of a clinical phase III trial comparing treosulfan to busulfan-based conditioning therapy prior to allogeneic hematopoietic stem cell transplantation of adult acute myeloid leukemia and myelodysplastic syndrome patients ineligible to standard myeloablative regimens. Biol Blood Marrow Transplant. 2019;25(3):S3. [Google Scholar]

33. Ciurea SO, Zhang M-J, Bacigalupo AA, et al. . Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033-1040. [PMC free article] [PubMed] [Google Scholar]

34. Eapen M, Rocha V, Sanz G, et al. ; National Cord Blood Program of the New York Blood Center. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653-660. [PMC free article] [PubMed] [Google Scholar]

35. Robinson TM, Fuchs EJ, Zhang MJ, et al. ; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research. Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?Blood Adv. 2018;2(11):1180-1186. [PMC free article] [PubMed] [Google Scholar]

36. Robin M, Porcher R, Ruggeri A, et al. . HLA-mismatched donors in patients with myelodysplastic syndrome: An EBMT Registry analysis. Biol Blood Marrow Transplant. 2019;25(1):114-120. [PubMed] [Google Scholar]

37. Guardiola P, Runde V, Bacigalupo A, et al. ; Subcommittee for Myelodysplastic Syndromes of the Chronic Leukaemia Working Group of the European Blood and Marrow Transplantation Group. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood. 2002;99(12):4370-4378. [PubMed] [Google Scholar]

38. del Cañizo MC, Martínez C, Conde E, et al. ; Grupo Español de Trasplante Hematopoyético. Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry. Bone Marrow Transplant. 2003;32(10):987-992. [PubMed] [Google Scholar]

39. Lee SJ, Logan B, Westervelt P, et al. . Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial. JAMA Oncol. 2016;2(12):1583-1589. [PMC free article] [PubMed] [Google Scholar]

40. Adhikari J, Sharma P, Bhatt VR. Optimal graft source for allogeneic hematopoietic stem cell transplant: bone marrow or peripheral blood?Future Oncol. 2016;12(15):1823-1832. [PubMed] [Google Scholar]

41. Genovese G, Jaiswal S, Ebert BL, McCarroll SA. Clonal hematopoiesis and blood-cancer risk. N Engl J Med. 2015;372(11):1071-1072. [PubMed] [Google Scholar]

42. Jaiswal S, Fontanillas P, Flannick J, et al. . Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498. [PMC free article] [PubMed] [Google Scholar]

43. Frick M, Chan W, Arends CM, et al. . Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019;37(5):375-385. [PubMed] [Google Scholar]

44. Kröger N, Zabelina T, de Wreede L, et al. ; MDS subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia. 2013;27(3):604-609. [PubMed] [Google Scholar]

45. Guièze R, Damaj G, Pereira B, et al. . Management of myelodysplastic syndrome relapsing after allogeneic hematopoietic stem cell transplantation: a study by the French Society of Bone Marrow Transplantation and Cell Therapies. Biol Blood Marrow Transplant. 2016;22(2):240-247. [PubMed] [Google Scholar]

46. Schroeder T, Rachlis E, Bug G, et al. . Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions–a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biol Blood Marrow Transplant. 2015;21(4):653-660. [PubMed] [Google Scholar]

47. de Lima M, Oran B, Champlin RE, et al. . CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. Biol Blood Marrow Transplant. 2018;24(10):2017-2024. [PMC free article] [PubMed] [Google Scholar]

48. Platzbecker U, Middeke JM, Sockel K, et al. . Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12):1668-1679. [PubMed] [Google Scholar]

49. Duncavage EJ, Jacoby MA, Chang GS, et al. . Mutation clearance after transplantation for myelodysplastic syndrome. N Engl J Med. 2018;379(11):1028-1041. [PMC free article] [PubMed] [Google Scholar]

50. Silverman LR, Demakos EP, Peterson BL, et al. . Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440. [PubMed] [Google Scholar]

51. Kantarjian H, Issa J-PJ, Rosenfeld CS, et al. . Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803. [PubMed] [Google Scholar]

52. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. ; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232. [PMC free article] [PubMed] [Google Scholar]

53. Lübbert M, Suciu S, Baila L, et al. . Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987-1996. [PubMed] [Google Scholar]

54. Fenaux P, Gattermann N, Seymour JF, et al. . Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol. 2010;149(2):244-249. [PMC free article] [PubMed] [Google Scholar]

55. Seymour JF, Fenaux P, Silverman LR, et al. . Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2010;76(3):218-227. [PMC free article] [PubMed] [Google Scholar]

56. Almasri J, Alkhateeb HB, Firwana B, et al. . A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome. Syst Rev. 2018;7(1):144. [PMC free article] [PubMed] [Google Scholar]

57. Mozessohn L, Cheung MC, Fallahpour S, et al. . Azacitidine in the ‘real-world’: an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. Br J Haematol. 2018;181(6):803-815. [PubMed] [Google Scholar]

58. Bernal T, Martínez-Camblor P, Sánchez-García J, et al. ; Spanish Society of Hematology. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015;29(9):1875-1881. [PubMed] [Google Scholar]

59. Itzykson R, Thépot S, Quesnel B, et al. ; Groupe Francophone des Myelodysplasies(GFM). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403-411. [PubMed] [Google Scholar]

60. Dinmohamed AG, van Norden Y, Visser O, et al. . Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry. Leukemia. 2015;29(12):2449-2451. [PubMed] [Google Scholar]

61. Kantarjian H, Oki Y, Garcia-Manero G, et al. . Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52-57. [PubMed] [Google Scholar]

62. Kuendgen A, Müller-Thomas C, Lauseker M, et al. . Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. Oncotarget. 2018;9(45):27882-27894. [PMC free article] [PubMed] [Google Scholar]

63. Takahashi K, Patel K, Bueso-Ramos C, et al. . Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016;7(12):14172-14187. [PMC free article] [PubMed] [Google Scholar]

64. Itzykson R, Kosmider O, Cluzeau T, et al. ; Groupe Francophone des Myelodysplasies (GFM). Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147-1152. [PubMed] [Google Scholar]

65. Idossa D, Lasho TL, Finke CM, et al. . Mutations and karyotype predict treatment response in myelodysplastic syndromes. Am J Hematol. 2018;93(11):1420-1426. [PubMed] [Google Scholar]

66. Sébert M, Renneville A, Bally C, et al. ; Groupe Francophone des Myélodysplasies (GFM). A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica. 2019;104(8):1565-1571. [PMC free article] [PubMed] [Google Scholar]

67. Savona MR, Odenike O, Amrein PC, et al. . An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019;6(4):e194-e203. [PubMed] [Google Scholar]

68. Sekeres MA, Othus M, List AF, et al. . Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017;35(24):2745-2753. [PMC free article] [PubMed] [Google Scholar]

69. Dickinson M, Cherif H, Fenaux P, et al. ; SUPPORT study investigators. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018;132(25):2629-2638. [PMC free article] [PubMed] [Google Scholar]

70. DiNardo CD, Pratz K, Pullarkat V, et al. . Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17. [PMC free article] [PubMed] [Google Scholar]

71. DiNardo CD, Watts JM, Stein EM, et al. . Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant relapsed or refractory myelodysplastic syndrome: results from a phase 1 dose escalation and expansion study. Blood. 2018;132(suppl 1):1812. [Google Scholar]

72. Sallman DA, DeZern AE, Steensma DP, et al. . Phase 1b/2 combination study of APR-246 and azacitidine (aza) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Blood. 2018;132(suppl 1):3901. [Google Scholar]

73. Garcia-Manero G, Sasaki K, Montalban-Bravo G, et al. . A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS). Blood. 2018;132(suppl 1):465. [Google Scholar]

74. Daver N, Boddu P, Garcia-Manero G, et al. . Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018;32(5):1094-1105. [PMC free article] [PubMed] [Google Scholar]

75. Kubasch AS, Schulze F, Gotze KS, et al. . Anti-CD123 targeted therapy with talacotuzumab in advanced MDS and AML after failing hypomethylating agents - final results of the Samba trial. Blood. 2018;132(suppl 1):4045. [Google Scholar]

76. Garcia-Manero G, Fenaux P, Al-Kali A, et al. ; ONTIME study investigators. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(4):496-508. [PubMed] [Google Scholar]

77. Navada SC, Garcia-Manero G, Atallah EL, et al. . Phase 2 expansion study of oral rigosertib combined with azacitidine (aza) in patients (pts) with higher-risk (HR) myelodysplastic syndromes (MDS): efficacy and safety results in HMA treatment naive and relapsed (Rel)/Refractory (Ref) patients. Blood. 2018;132(suppl 1):230. [Google Scholar]

78. Voso MT, Leone G, Piciocchi A, et al. . Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Ann Oncol. 2017;28(7):1547-1553. [PubMed] [Google Scholar]


Emerging treatment options for patients with high-risk myelodysplastic syndrome

1. Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J 2018; 8: 47. [PMC free article] [PubMed] [Google Scholar]

2. Bewersdorf JP, Zeidan AM. Transforming growth factor (TGF)-ß pathway as a therapeutic target in lower risk myelodysplastic syndromes. Leukemia 2019; 33: 1303–1312. [PubMed] [Google Scholar]

3. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–2405. [PubMed] [Google Scholar]

4. Platzbecker U. Treatment of MDS. Blood 2019; 133: 1096–1107. [PubMed] [Google Scholar]

5. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465. [PMC free article] [PubMed] [Google Scholar]

6. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088. [PubMed] [Google Scholar]

7. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503–3510. [PubMed] [Google Scholar]

8. Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017; 15: 60–87. [PubMed] [Google Scholar]

9. Stahl M, Zeidan AM. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Expert Rev Hematol 2017; 10: 345–364. [PubMed] [Google Scholar]

10. Stahl M, Bewersdorf JP, Giri S, et al. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica 2020; 105: 102–111. [PMC free article] [PubMed] [Google Scholar]

11. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232. [PMC free article] [PubMed] [Google Scholar]

12. Voso MT, Leone G, Piciocchi A, et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Ann Oncol 2017; 28: 1547–1553. [PubMed] [Google Scholar]

13. de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood 2017; 129: 1753–1762. [PMC free article] [PubMed] [Google Scholar]

14. Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006; 106: 1099–1109. [PubMed] [Google Scholar]

15. Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29: 1987–1996. [PubMed] [Google Scholar]

16. Zeidan AM, Stahl M, DeVeaux M, et al. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?Blood Cancer J 2018; 8: 55. [PMC free article] [PubMed] [Google Scholar]

17. Santini V. How I treat MDS after hypomethylating agent failure. Blood 2019; 133: 521–529. [PubMed] [Google Scholar]

18. Jabbour EJ, Garcia-Manero G, Strati P, et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer 2015; 121: 876–882. [PMC free article] [PubMed] [Google Scholar]

19. Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29: 3322–3327. [PMC free article] [PubMed] [Google Scholar]

20. Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010; 116: 3830–3834. [PMC free article] [PubMed] [Google Scholar]

21. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150: 12–27. [PubMed] [Google Scholar]

22. Feinberg AP. The key role of epigenetics in human disease prevention and mitigation. N Engl J Med 2018; 378: 1323–1334. [PubMed] [Google Scholar]

23. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241–247. [PMC free article] [PubMed] [Google Scholar]

24. Bejar R, Papaemmanuil E, Haferlach T, et al. Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the international working group for prognosis in MDS-molecular committee. Blood 2015; 126: 907. [Google Scholar]

25. Mossner M, Jann JC, Wittig J, et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood 2016; 128: 1246–1259. [PubMed] [Google Scholar]

26. Bewersdorf JP, Shallis R, Stahl M, et al. Epigenetic therapy combinations in acute myeloid leukemia: what are the options?Ther Adv Hematol 2019; 10: 2040620718816698. [PMC free article] [PubMed] [Google Scholar]

27. Uy N, Singh A, Gore SD, et al. Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings. Expert Opin Pharmacother 2017; 18: 1213–1224. [PMC free article] [PubMed] [Google Scholar]

28. Issa J-PJ, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009; 15: 3938–3946. [PMC free article] [PubMed] [Google Scholar]

29. Kantarjian HM, Roboz GJ, Kropf PL, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol 2017; 18: 1317–1326. [PMC free article] [PubMed] [Google Scholar]

30. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57. [PubMed] [Google Scholar]

31. Garcia-Manero G, Roboz G, Walsh K, et al. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol 2019; 6: e317–e327. [PubMed] [Google Scholar]

32. Garcia-Manero G, Griffiths EA, Roboz GJ, et al. A phase 2 dose-confirmation study of oral ASTX727, a combination of oral decitabine with a cytidine deaminase inhibitor (CDAi) cedazuridine (E7727), in subjects with myelodysplastic syndromes (MDS). Blood 2017; 130(Suppl. 1): 4274. [Google Scholar]

33. Savona MR, Kolibaba K, Conkling P, et al. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. Am J Hematol 2018; 93: 1199–1206. [PMC free article] [PubMed] [Google Scholar]

34. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009; 27: 1850–1856. [PubMed] [Google Scholar]

35. Müller-Thomas C, Schuster T, Peschel C, et al. A limited number of 5-azacitidine cycles can be effective treatment in MDS. Ann Hematol 2009; 88: 213–219. [PubMed] [Google Scholar]

36. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011; 117: 2697–2702. [PMC free article] [PubMed] [Google Scholar]

37. Voso MT, Breccia M, Lunghi M, et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol 2013; 90: 345–348. [PubMed] [Google Scholar]

38. Platzbecker U. Treatment of MDS. Blood 2019; 133: 1096–1107. [PubMed] [Google Scholar]

39. Prebet T, Fenaux P, Vey N; Groupe Francophone des Myelodysplasies. Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system. Haematologica 2016; 101: e427–e428. [PMC free article] [PubMed] [Google Scholar]

40. Nazha A, Sekeres MA, Komrokji R, et al. Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer J 2017; 7: 644. [PMC free article] [PubMed] [Google Scholar]

41. Nazha A, Komrokji RS, Garcia-Manero G, et al. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica 2016; 101: e224–e227. [PMC free article] [PubMed] [Google Scholar]

42. Prebet T, Charbonnier A, Gelsi-Boyer V, et al. Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Leuk Lymphoma 2013; 54: 1538–1540. [PubMed] [Google Scholar]

43. Cherian MA, Tibes R, Gao F, et al. A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome

  1. Usmc endurance course
  2. Zodiac signs colors
  3. Mcpe sound list

Higher-Risk Myelodysplastic Syndromes: Lacking Treatment Advances in Over a Decade

Other options like allogeneic stem cell transplantation (ASCT) have the potential to cure HR-MDS, but many patients may not be eligible because they may be too frail or sick to tolerate the procedure or may not have a suitable donor.15-16 Due to age or comorbidities, only 6% to 14% of people living with HR-MDS undergo ASCT. Even patients who are eligible to receive ASCT have relatively poor outcomes, as transplant-related mortality ranges from 20% to 37%.17-18

In the event that neither chemotherapy nor ASCT are options, supportive care alternatives, such as transfusions or blood cell growth factors can help manage symptoms, but have no efficacy against the disease itself.15,19

A significant need remains for targeted therapies for those living with HR-MDS.

For over a decade, there has been little advancement in treatment options for people living with HR-MDS despite poor patient outcomes.

Continued research is critical to potentially bring a targeted therapeutic option to HR-MDS patients, to not only improve OS, but also to manage symptoms and preserve quality of life. Though there has been little progress in HR-MDS treatment options over the last decade, late-stage clinical studies are actively investigating novel agents in combination with HMAs to improve efficacy and patient outcomes while maintaining safety and tolerability. Due to its aggressive nature and poor survival rates, people living with HR-MDS urgently require new treatment options that are more effective at inducing remission and slowing or preventing disease progression to ultimately improve the survival and quality of life of patients living with this disease.

Author Disclosure: Dr. Watts has received consultancy fees from Takeda/Millennium Pharmaceuticals, Genentech, Jazz Pharmaceuticals, and Rafael Pharmaceuticals.

Acknowledgements: The author would like to acknowledge W2O Group for their writing support, which was funded by Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Sponsored by Takeda Oncology.


  1. American Cancer Society. What Are Myelodysplastic Syndromes? Accessed April 3, 2020.
  2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Myelodysplastic Syndromes, Chronic Myeloproliferative Disorders, and Chronic Myelomonocytic Leukemia. Accessed April 3, 2020.
  3. American Cancer Society. Signs and Symptoms of Myelodysplastic Syndromes. Accessed April 3, 2020.
  4. American Cancer Society. Tests for Myelodysplastic Syndromes. Accessed April 3, 2020.
  5. Leukemia & Lymphoma Society. The International Prognostic Scoring System. Accessed April 3, 2020.
  6. MDS Foundation. Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator. Accessed April 3, 2020.
  7. Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., … Haase, D. (2012). Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood, 120(12), 2454—2465. doi:10.1182/blood-2012-03-420489.
  8. American Cancer Society. Survival Statistics for Myelodysplastic Syndromes. Accessed April 3, 2020.
  9. The Aplastic Anemia and MDS International Foundation. Acute Myeloid Leukemia (AML). Accessed April 3, 2020.
  10. Ma, Y., Shen, J., & Wang, L. X. (2018). Successful Treatment of High-Risk Myelodysplastic Syndrome with Decitabine-Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion: A Case Report and Literature Review. Medicine, 97(16), e0434. doi:10.1097/MD.0000000000010434.
  11. Mayo Clinic. Acute Myelogenous Leukemia. Accessed April 3, 2020.
  12. Kumar C. C. (2011). Genetic Abnormalities and Challenges in the Treatment of Acute Myeloid Leukemia. Genes & cancer, 2(2), 95—107. doi:10.1177/1947601911408076
  13. American Cancer Society. Facts & Figures 2020 Reports Largest One-year Drop in Cancer Mortality. Accessed April 3, 2020.
  14. Clinical Advances in Hematology & Oncology. Hypomethylating Agents in Myelodysplastic Syndromes. Accessed April 3, 2020.
  15. American Cancer Society. General Approach to Treatment of Myelodysplastic Syndromes. Accessed April 3, 2020.
  16. American Cancer Society. Stem Cell Transplant for Myelodysplastic Syndrome. Accessed April 3, 2020.
  17. Della Porta, M.G., Alessandrino, E.P., Bacigalupo, A., van Lint, M.T., Malcovati, L., … Rambaldi, A. Predictive Factors for the Outcome of Allogeneic Transplantation in Patients with MDS Stratified According to the Revised IPSS-R. Blood 2014; 123 (15): 2333—2342. doi:
  18. Lozano, S., Olavarria, E., Iacobelli, S., van Biezen, A., Beelen, D.W., … Robin, M. The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. Blood 2015; 126 (23): 3223. doi:
  19. Malcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., Del Cañizo, C., …Cazzola, M. European Leukemia Net (2013). Diagnosis and Treatment of Primary Myelodysplastic Syndromes in Adults: Recommendations from the European LeukemiaNet. Blood, 122(17), 2943—2964. doi:10.1182/blood-2013-03-492884
A Unified Approach to Higher Risk MDS: Standard and Emerging Therapies

What to know about higher-risk myelodysplastic syndromes (HR-MDS) [Infographic]

(BPT) - Sponsored by Takeda Oncology

MDS is a rare cancer that is not commonly discussed, and is often referred to as a disorder or condition.

In recognition of MDS World Awareness Day, here are three key things to know about MDS:

What is MDS?

MDS is a rare form of bone marrow cancer.1 There are 14,000 cases of MDS reported every year in the U.S., ranging in prognosis from very low- to very high-risk.2 Approximately 43% of new cases are higher-risk, meaning patients are at an increased risk for poor outcomes.3

Why is it important that MDS should be widely considered a cancer?

MDS can be difficult to identify because symptoms are often vague, and patients are typically 70 years or older.4 MDS can be classified as higher-risk disease, which is often fatal. HR-MDS can transform into another aggressive cancer, acute myeloid leukemia (AML), which also has extremely poor survival outcomes.1 Greater recognition of MDS as a cancer could lead to greater urgency to treat patients.

Are there any treatment options available for HR-MDS?

Stem cell transplants are the only potential curative option, but the vast majority of people are too frail or sick to undergo transplant.5 A specific type of chemotherapy — hypomethylating agents (HMAs) — is approved to treat HR-MDS, but, alone, provides limited benefit.6 There have been no novel advances in treatment for HR-MDS in over 10 years.7-8


1 American Cancer Society. Accessed August 27, 2020.

2 National Cancer Institute. Accessed August 27, 2020.

3 Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sol�, F., … Haase, D. (2012). Blood, 120(12), 2454–2465. Accessed August 27, 2020.

4 American Cancer Society. Accessed August 27, 2020.

5 American Cancer Society. Accessed June 8, 2020.

6 Gil-Perez, A., Montalban-Bravo, G. (2019). Therapeutic Advances in Hematology, 10, 2040620719847059. Accessed August 27, 2020.

7 Gotza, K.S., Muller-Thomas, C., Peschel, C. (2009). Cancer Management and Research, 1, 119-130. Accessed August 27, 2020.

8 National Comprehensive Cancer Network. Accessed August 27, 2020.


Mds hr

Myelodysplastic Syndromes (MDS) are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells. MDS is often referred to as a “bone marrow failure disorder”. MDS is primarily a disease of the elderly (most patients are older than age 65), but MDS can affect younger patients as well. To help you better understand MDS, it might be helpful to first consider some basics about bone marrow and blood. The bone marrow functions as a factory that manufactures three kinds of blood cells: red blood cells, white blood cells, and platelets. Healthy bone marrow produces immature blood cells — called stem cells, progenitor cells, or blasts — that normally develop into mature, fully functional red blood cells, white blood cells, and platelets. In MDS, these stem cells may not mature and may accumulate in the bone marrow or they may have a shortened life span, resulting in fewer than normal mature blood cells in the circulation.

Low blood cell counts, referred to as cytopenias, are a hallmark feature of MDS and are responsible for some of the symptoms that MDS patients experience — infection, anemia, spontaneous bleeding, or easy bruising. Anemia (low red blood cell counts), neutropenia (low white blood cell counts), and thrombocytopenia (low platelet counts) are the major types of blood cell cytopenias, and are discussed below. In addition to reduced numbers of blood cells, the mature blood cells circulating in the blood may not function properly because of dysplasia. The formal definition of dysplasia is the abnormal shape and appearance, or morphology, of a cell. The prefix myelo- is from the Greek and it means marrow; so myelodysplasia refers to the abnormal shape and appearance — or morphology — of the mature blood cells. Syndromes comes from the Greek and means a set of symptoms that occur together.

Failure of the bone marrow to produce mature healthy cells is a gradual process, and therefore MDS is not necessarily a terminal disease. Some patients do succumb to the direct effects of the disease: reduced blood cell and/or reduced platelet counts may be accompanied by the loss of the body’s ability to fight infections and control bleeding. In addition, for roughly 30% of the patients diagnosed with MDS, this type of bone marrow failure syndrome will progress to acute myeloid leukemia (AML).

To read more about the effects of MDS on blood cells, click here to view our complete handbook.


With a few exceptions, the exact causes of MDS are unknown. Some evidence suggests that certain people are born with a tendency to develop MDS. This tendency can be thought of as a switch that is triggered by an external factor. If the external factor cannot be identified, then the disease is referred to as “primary MDS”.

Radiation and chemotherapy for cancer are among the known triggers for the development of MDS. Patients who take chemotherapy drugs or who receive radiation therapy for potentially curable cancers, such as breast or testicular cancers, Hodgkin’s disease and non-Hodgkin’s lymphoma, are at risk of developing MDS for up to 10 years following treatment. MDS that develops after use of cancer chemotherapy or radiation is called “secondary MDS” and is usually associated with multiple chromosome abnormalities in cells in the bone marrow. This type of MDS often develops rapidly into AML.

Long term exposure to certain environmental or industrial chemicals, such as benzene, can also trigger MDS. While benzene use is now highly regulated, it is not clear which other chemicals may predispose individuals to MDS, although certain occupations have been labeled “at risk” for the development of MDS or AML (e.g., painters, coal miners, embalmers). There are no known food or agricultural products that cause MDS. While alcohol consumed on a daily basis may lower red blood cell and platelet counts, alcohol does not cause MDS. There is insufficient data available to determine if smoking increases the risk of developing MDS. However, it is known that the risk of developing AML is 1.6 times greater for smokers than for non-smokers.

Patients and their families often worry that MDS might be contagious. No evidence exists to suggest that a virus causes MDS; thus, MDS cannot be transmitted to loved ones.

MDS is not inherited. In fact, it is a very rare occasion when family members, including siblings, are diagnosed with MDS.


In the early stages of MDS patients may experience no symptoms at all. A routine blood test may reveal a reduced red cell count, or low hematocrit, sometimes along with reduced white cell and/or reduced platelet counts. On occasion, the white cell and platelet counts may be low while the hematocrit remains normal. However, some patients, particularly those with blood cell counts well below normal, experience definite symptoms. These symptoms, described below, depend on which blood cell type is involved as well as the level of the cell count.


The majority of individuals are anemic when they are initially diagnosed with MDS. Anemia is characterized by a persistently low hematocrit (a measure of the body’s red blood cells) or persistently low levels of hemoglobin (the blood protein that carries oxygen to the body’s tissues). Anemic patients generally experience fatigue and report that they are tired much of the time and have no energy. Anemia varies in its severity. In mild anemia, patients may feel well or just slightly fatigued. In moderate anemia, almost all patients experience some fatigue, which may be accompanied by heart
palpitations, shortness of breath, and pale skin. In severe anemia, almost all patients appear pale and report chronic overwhelming fatigue and shortness of breath. Because severe anemia reduces blood flow to the heart, older patients may be more likely to experience cardiovascular symptoms, including chest pain. Although chronic anemia is seldom life threatening, it can drastically reduce a patient’s quality of life.


A reduced white cell count lowers the body’s resistance to bacterial infection. Patients with neutropenia may be susceptible to skin infections, sinus infections (symptoms include nasal congestion), lung infections (symptoms include cough, shortness of breath), or urinary tract infections (symptoms include painful and frequent urination). Fever may accompany these infections.


Patients with thrombocytopenia have an increased tendency to bruise and bleed even after minor bumps and scrapes. Nosebleeds are common and patients often experience bleeding of the gums, particularly after dental work. Before having dental work, consultation with your hematologist, who may prescribe the prophylactic use of antibiotics, is recommended since infection and bleeding pose a risk for most MDS patients.

What can I do to help?

There are many ways that you can support those diagnosed with MDS. You can learn more about MDS from our website, and by reading materials such as our Building Blocks of Hope program.

You can also support the MDS Foundation in our efforts. You can learn more about the Foundation here, and can click here to make a tax-deductible donation.

For more information, feel free to contact us directly.

Sabatolimab plus HMAs in patients with HR-MDS and AML

What is MDS

MDS are a group of a progressive bone marrow diseases characterized by failure of the bone marrow to generate normal blood cells. The bone marrow is the organ in the human body that makes blood cells that are essential for critical physiologic functions. These cells include platelets (also called thrombocytes) that make your blood clot, red blood cells (erythrocytes) that carry oxygen in your blood, and most of the white blood cells in our bodies that fight infection. For these cells to carry out their functions, they must be produced in adequate numbers and must be functioning normally. In patients with MDS, the blood cells that are produced are too few in number and they are dysfunctional.

Blood cells are formed from stem cells in the bone marrow. The diagram below illustrates this process and it shows which kinds of blood cells are ultimately affected in MDS.

Hematopoiesis Image

Source: Wikipedia

As the diagram shows, MDS is a disease associated with cells in the myeloid lineage. When myeloid cells look abnormal under the microscope, they are called dysplastic. Thus, the name of the disease: myelodysplastic. Because MDS patients have too few or improperly functioning blood cells, their blood does not clot properly and they are at higher risk for life-threatening infections than people who don’t have MDS. In addition, about 1/3rd of patients who have MDS are at risk for developing a blood cancer called acute myeloid leukemia (AML).

MDS is diagnosed in least 10,000 people each year in the United States, and approximately 60,000 people are living with the disease in the US today. Most cases of MDS occur in people age 70 or older. About 90% of MDS patients have what is called de novo MDS, meaning the disease arises with no apparent cause. Approximately 10% of patients get MDS because of prior treatment for cancer, e.g., with chemotherapy or radiation, and are therefore said to have therapy-related MDS. A very small proportion of patients have MDS as a result of an inherited genetic condition affecting their bone marrow, such as Fanconi anemia. These patients are typically children, and the types of MDS that children get are generally different from the MDS that adults get. There are also some other bone marrow diseases, called MDS/MPD (where MPD means myeloproliferative disorders), that look a little bit like MDS but have some unique characteristics of their own. More research is required to understand the nature of MDS/MPD and how best to treat them.

MDS can be divided into high risk and low risk disease, where higher risk MDS is associated with a greater chance of death or transformation to AML. The only way to cure MDS is through a stem cell transplant. Stem cells can be obtained from many sources, including bone marrow, blood, or umbilical cord blood. Unfortunately, stem cell transplants are not possible for all MDS patients because sometimes it is difficult to find a stem cell donor, and not all patients are healthy enough to undergo the procedure. There are other drugs available to treat MDS, and although some may prolong survival by a small amount, many simply treat the symptoms of MDS and none have the potential to cure the disease. Therefore, it is very important that more research be done to develop a cure for MDS.


Now discussing:

ON THIS PAGE: You will learn about how doctors describe MDS. This is called subtype and classification. Use the menu to see other pages.

MDS is classified into several different subtypes based on the following features:

  • Blood cell counts

  • Percentage of blasts in the bone marrow

  • Risk that it will turn into AML

It is also classified as either primary MDS or secondary MDS. And, MDS is given a stage called an IPSS-R score. These classifications help doctors plan treatment and predict a patient’s prognosis, which is the chance of recovery. Each is described below in more detail.

WHO system for MDS subtypes

The World Health Organization (WHO) developed a classification system for MDS to standardize the definitions of the different subtypes. The 7 subtypes of MDS in this system include:

  • Refractory anemia (RA). The primary sign of RA is anemia. White blood cell counts and platelet counts are healthy. There are less than 5% blasts found in the bone marrow. This subtype of MDS does not often turn into AML.

  • Refractory anemia with ringed sideroblasts (RARS). People with this subtype of MDS have anemia, similar to those with RA, except more than 15% of the red blood cells are sideroblasts. A sideroblast is a red blood cell in which the iron in the cell appears to be in a ring around the center of the cell where the genes are found, called the nucleus. The white blood cell and platelet counts are usually healthy. People diagnosed with RARS have a low risk of developing AML.

  • Refractory cytopenia with multilineage dysplasia (RCMD). In this subtype, people have less than 5% blasts and less than 15% ringed sideroblasts in the bone marrow. The other bone marrow cells look abnormal when viewed under the microscope. At least 2 of the blood cell counts are low. RCMD may eventually turn into AML.

  • Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). This subtype is similar to RARS, in which people have anemia and more than 15% sideroblasts. The other bone marrow cells also look abnormal when viewed with a microscope. In addition, at least 2 types of blood cell counts are low. RCMD-RS may eventually turn into AML.

  • Refractory anemia with excess blasts (RAEB). People with RAEB can have decreases in all or some of their blood cell counts. There are less than 5% blast cells in the blood and 5% to 20% blasts in the bone marrow. People with more than 20% blasts in the bone marrow are diagnosed with AML. People with RAEB may also have lower white blood cell and platelet counts. About 40% of people diagnosed with RAEB eventually develop AML.

  • Myelodysplastic syndrome, unclassified (MDS-U). People diagnosed with this subtype have decreased numbers of white blood cells, red blood cells, or platelets, but do not have the specific signs of the other MDS subtypes.

  • MDS associated with isolated del(5q). People with this subtype have anemia and fewer than 5% blasts, and genetic material is missing from chromosome 5.

  • CMML and JMML. In addition to the 7 MDS subtypes above, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) are types of blood cancers that the WHO classifies as “mixed myelodysplastic/myeloproliferative diseases.” Unlike other types of MDS in which blood counts are low, white blood cell counts are higher in these subtypes. Both CMML and JMML begin after a change, or mutation, happens in a type of blood cell called a monocyte. CMML generally occurs in people ages 65 to 75. JMML is most common in children younger than 6. Treatment is similar to MDS and can include chemotherapy and/or stem cell transplantation (see Types of Treatment).

Primary/secondary MDS

In addition to subtype, MDS is called either primary or secondary MDS. Primary MDS is much more common than secondary MDS. About 80% of people with MDS have primary MDS.

  • In primary MDS, no apparent risk factors can be found. This may also be called de novo MDS.

  • Secondary MDS occurs because of damage to the DNA from chemotherapy or radiation therapy previously given to treat another medical condition. MDS can develop 2 to 10 years after such treatment. Secondary MDS is often associated with more complex chromosomal abnormalities.

IPSS-R system

The revised International Prognostic Scoring System (IPSS-R) is another classification system used by doctors to help predict a person’s risk of developing AML and overall survival. The IPSS-R looks at factors such as the percentage of blasts found in the bone marrow, type and extent of chromosomal changes, and levels of hemoglobin found in red blood cells, platelets, and a type of white blood cell called neutrophils.

Poor prognostic factors include:

  • Certain types and higher numbers of chromosomal changes

  • Higher percentage of blasts in the bone marrow

  • Low levels of hemoglobin, platelets, and neutrophils

The total IPSS-R score places people with MDS into 5 distinct groups:

  • Very low risk

  • Low risk

  • Intermediate risk

  • High risk

  • Very high risk

People with MDS who have a lower IPSS-R score have the best outlook for survival and need less aggressive treatment. For patients with lower IPSS-R scores, overall survival rates tend to be lower when they need red blood cell transfusions. A red blood cell transfusion is a procedure in which blood or blood cells from 1 person are given to another person. A person diagnosed with a high-risk subtype of MDS and whose IPSS-R score is high usually needs more intensive treatment.

Recurrent MDS

Recurrent MDS is MDS that has come back after a period of remission, or absence of symptoms, also called “no evidence of disease” or NED. If the MDS does return, there will be another round of tests to learn about the extent of the recurrence. These tests and scans are often similar to those done at the time of the original diagnosis.

Information about the subtype and classification will help the doctor recommend a specific treatment plan. The next section in this guide is Types of Treatment. Use the menu to choose a different section to read in this guide.


3952 3953 3954 3955 3956